Company intelligence / Profile preview

Vaxon Biotech

Paris or Marly-le-Roi, Île-de-France, Francevaxon-biotech.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Vaxon Biotech develops innovative immunotherapeutic vaccines for various cancers using a proprietary optimized cryptic peptide technology. Its lead candidate, Vx‑001, completed a multicenter Phase IIb trial in non-small cell lung cancer showing significant survival benefit in never/light smokers with non-immunogenic tumors. The company’s pipeline includes several vaccine candidates targeting universal tumor antigens across multiple solid tumors. Vx‑001 has received orphan drug designation from both EMA and FDA for NSCLC.

Therapeutic areas: Oncology
Modalities: Therapeutic vaccinesBiological products
Industry: Biotech

Drug pipeline

5 assets

vx-001

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Vaxon Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxon Biotech.

Explore the full profile